Related Experiment Video
Updated: Feb 17, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
Intraindividual Pharmacokinetic Variability: Focus on Small-Molecule Kinase Inhibitors
Etienne Chatelut1, René Bruno2, Mark J Ratain3
1Institut Claudius-Regaud, IUCT-Oncopole, CRCT, Université de Toulouse, Inserm, Toulouse, France.
Abstract:
The magnitude of interindividual pharmacokinetic variability (IIV) of a drug and the factors responsible for this variability are intensively studied before-and sometimes after-registration as crucial information in anticipating and understanding variability in toxicity and efficacy. However, there has been much less attention paid to intraindividual variability, reflecting random or systematic changes in an individual's pharmacokinetics over time. We have chosen to focus on small-molecule kinase inhibitors (SMKIs).
Related Concept Videos
Dosage Regimen: Individualization
Pharmacogenetics of Drug Metabolism: Overview
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Nonlinear Pharmacokinetics: Role of Transporters
Polymorphisms occurring in drug transporters can alter...
Nonlinear Pharmacokinetics: Causes of Nonlinearity
Nonlinear drug absorption can occur when the process is rate-limited by solubility, carrier-mediated transport systems, or saturation of the presystemic gut wall or hepatic metabolism. For instance, high doses of riboflavin...
Drug toxicity: Idiosyncratic Reactions

